证券时报·数据宝统计，截至发稿，海特生物收盘价为52.38元，上涨3.76%，本期筹码集中以来股价累 计下跌7.01%。具体到各交易日，4次上涨，5次下跌。 海特生物8月13日披露，截至8月10日公司股东户数为14433户，较上期（7月31日）减少2115户，环比降 幅为12.78%。 公司发布的一季报数据显示，一季度公司共实现营业收入1.57亿元，同比增长18.79%，实现净利 润-1393.04万元，同比增长15.81%，基本每股收益为-0.1100元。（数据宝） （文章来源：证券时报网） ...

证券之星消息，8月13日生物制品板块较上一交易日上涨1.6%，欧林生物领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688319 | 欧林生物 | 24.02 | 17.17% | 17.21万 | | 3.83亿 | | 688488 | 文迪药业 | 16.65 | 7.56% | 20.39万 | | 3.30亿 | | 688443 | 智翔金泰 | 35.15 | 6.97% | 10.04万 | | 3.43 Z | | 002773 | 康弘药业 | 44.49 | 5.48% | 10.18万 | | 4.47亿 | | 301080 | 百普赛斯 | 57.12 | 5.47% | 3.98万 | | 2.24亿 | | 688180 | 君实生物 | 43.46 | 5.03% | 23.94万 | | 10.25亿 | | ...

Core Viewpoint - Securities firms have provided "buy" ratings for over 20 A-share listed companies on August 13, focusing on industries such as liquor, transportation equipment, complete automobiles, bioproducts, consumer electronics, and auto parts [1] Group 1: Company Ratings - Kweichow Moutai received significant attention from securities firms, with five reports on August 13, ranking first among recommended stocks. Guojin Securities projected net profits of 93.4 billion, 98.8 billion, and 105.4 billion yuan for 2025-2027, with year-on-year growth rates of +8.4%, +5.8%, and +6.6% respectively, maintaining a "buy" rating [4] - Yanjing Beer was also highlighted, with five reports in the past month. Pacific Securities forecasted revenue growth rates of 6%, 5%, and 4% for 2025-2027, and net profit growth rates of 44%, 19%, and 11% respectively, assigning a target price of 14.58 yuan and a "hold" rating [4] - Chuanfeng Power, a leader in the all-terrain vehicle industry, received attention from four securities firms, ranking third among recommended stocks on August 13 [5] Group 2: Industry Insights - The liquor industry, particularly Kweichow Moutai and Yanjing Beer, is experiencing strong interest from analysts, indicating a positive outlook for major players in this sector [4] - The transportation equipment sector, represented by Chuanfeng Power, is benefiting from high-end market trends and product innovation, suggesting growth potential [5] - Other companies such as BYD, Jinbo Biological, Industrial Fulian, Fuda Co., Rongbai Technology, China Unicom, and Aobi Zhongguang have also garnered attention from multiple securities firms, indicating a broad interest across various industries [5]

Core Points - Fudan Zhangjiang reported a revenue of 390,083,112 yuan for the first half of 2025, representing a year-on-year decrease of 4.42% [2] - The net profit attributable to shareholders of the listed company was 5,715,142 yuan, showing a significant year-on-year decline of 91.89% [2] Financial Performance - The company's revenue for the first half of 2025 was 390.08 million yuan, down from the previous year [2] - The net profit for the same period was 5.72 million yuan, indicating a drastic reduction compared to the prior year [2]

Group 1 - The core point of the article highlights the financing activities of Innotec, with a net buying amount of 9.196 million yuan on August 12, ranking 904th in the market [1] - Over the last three trading days from August 8 to August 12, Innotec received financing purchases of 15 million yuan, 23 million yuan, and 21 million yuan respectively [1] Group 2 - On the same day, there were no shares sold or net sold in the securities lending market for Innotec [2]

Group 1 - The core viewpoint of the news is that Maiwei Biotech has seen significant financing activity, indicating investor interest in the company [1][2]. - On August 12, Maiwei Biotech had a financing buy-in amount of 0.53 billion, ranking 399th in the market, with a financing repayment amount of 0.45 billion, resulting in a net buy of 7.34 million [1]. - Over the last three trading days (August 8-12), the financing buy-in amounts for Maiwei Biotech were 0.43 billion, 0.39 billion, and 0.53 billion respectively [2]. Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no short selling activity [3].

Group 1 - As of August 12, 2025, the stock price of Shuyou Shen is reported at 49.85 yuan, down by 2.15 yuan, a decline of 4.13% from the previous trading day [1] - The stock reached a high of 52.79 yuan and a low of 49.54 yuan during the trading session, with a total trading volume of 7.59 billion yuan and a turnover rate of 3.18% [1] - Shuyou Shen operates in the biopharmaceutical sector, focusing on the research and production of innovative drugs, including monoclonal antibodies and other innovative therapies, particularly for neurological and immune system diseases [1] Group 2 - On August 12, the stock price of Shuyou Shen experienced a rapid decline of over 2% within the first five minutes of trading, indicating significant short-term market volatility [1] - In terms of capital flow, on August 12, there was a net outflow of 102 million yuan from main funds, accounting for 0.43% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 146 million yuan, representing 0.62% of the circulating market value [1]

证券代码：688739 证券简称：成大生物 公告编号：2025-041 辽宁成大生物股份有限公司 关于公司董事变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 辽宁成大生物股份有限公司（以下简称"成大生物"或"公司"）董事会于 近日收到董事董丙建先生与崔建伟先生的书面辞职报告。因工作需要，董丙建先 生申请辞去公司董事及董事会战略委员会委员职务，辞职后将不再担任公司任何 职务；崔建伟先生申请辞去公司董事职务，辞职后仍将担任公司副总经理、财务 总监职务。根据公司控股股东辽宁成大股份有限公司推荐、经董事会提名委员会 资格审查通过，董事会同意提名徐飚先生、周岳先生为公司第五届董事会非独立 董事候选人，任期自公司股东会审议通过之日起至第五届董事会届满之日止。该 议案尚需提交公司股东会审议。 公司于 2025 年 8 月 12 日召开第五届董事会第二十一次会议，审议通过了 《关 于补选公司董事的议案》。根据公司控股股东辽宁成大股份有限公司推荐、经董 事会提名委员会资格审查通过，董事会提名徐飚先生、周岳先生为公司第 ...

辽宁成大生物股份有限公司 信息披露管理制度 辽宁成大生物股份有限公司 信息披露管理制度 第一章 总 则 第一条 为提高辽宁成大生物股份有限公司（以下简称"公司"）信息披露工作质 量和规范信息披露行为，确保公司对外信息披露工作的真实性、准确性、及时性，保 护公司、股东、债权人及其他利益相关者的合法权益，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司信息披露管理办法》（以下简称"《管理办法》"）《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）及其他有关法律、法规、规范性 文件和《辽宁成大生物股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 本制度所称"信息披露"是指公司将对公司股票及其衍生品种交易价格可 能产生较大影响而投资者尚未得知的信息或影响投资者作出价值判断和投资决策的重 大信息，在规定的期限内，通过上海证券交易所网站和符合中国证监会规定条件的媒 体，以规定的方式向社会公众公布，并按照规定报送证券监管部门。 第三条 本制度适用于如下人员和机构： (一) 公司董事会秘书和信息披露事务管理部门； ...

General Principles - The purpose of the independent director system is to enhance the corporate governance structure of Liaoning Chengda Biological Co., Ltd. and create a favorable working environment for independent directors [1][2] - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could hinder their independent judgment [1][2] Independent Director Responsibilities - Independent directors have a duty of loyalty and diligence to the company and all shareholders, and they must perform their duties in accordance with relevant laws and the company's articles of association [1][2] - They are required to participate in decision-making, supervision, and provide professional advice to protect the overall interests of the company and the legal rights of minority shareholders [1][2] Qualifications and Independence - Independent directors must meet specific qualifications, including having at least five years of relevant work experience and a good personal character without significant credit issues [2][3] - The company must ensure that independent directors maintain their independence and are not influenced by major shareholders or actual controllers [2][3] Nomination and Election - Independent directors can be nominated by the board of directors or shareholders holding more than 1% of the company's issued shares, and their qualifications must be reviewed before nomination [5][6] - The election of independent directors must be conducted separately from non-independent directors, and cumulative voting is required when electing multiple independent directors [6][14] Duties and Powers - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing objective advice to enhance decision-making quality [18][19] - They have special powers, including the ability to hire external consultants, propose meetings, and express independent opinions on matters that may harm the company or minority shareholders [19][20] Communication and Reporting - The company must establish a communication mechanism between independent directors and minority shareholders, allowing independent directors to verify investor inquiries [29] - Independent directors are required to submit annual reports on their performance to the company's annual general meeting [30] Support and Compensation - The company must provide necessary working conditions and support for independent directors to fulfill their responsibilities [32][33] - Independent directors are entitled to compensation that corresponds to their responsibilities, which must be approved by the shareholders' meeting and disclosed in the annual report [38]